Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

Novimmune S.A.. (9/2/15). "Press Release: Novimmune and Baxalta Ink International Bispecific Antibody Collaboration". Geneva.

Organisations Organisation Novimmune S.A.
  Organisation 2 Baxalta Inc. (NYSE: BXLT)
  Group Shire (Group)
Products Product bispecific antibody
  Product 2 kappa/lambda body™ bispecific drug platform
Index term Index term Baxalta–Novimmune: therapeutic antibodies, 201509– collab r+d €na bispecific antibodies for hemophilia A
Person Person Barbut, Jack (Novimmune 201012–201512 CEO until 12/15)

Novimmune SA announced today that it has signed an international research collaboration agreement with Baxalta Incorporated to develop novel bispecific antibodies for an unspecified indication. Financial terms of the deal were not disclosed.

This is the first collaboration utilizing Novimmune's new kappa-lambda bispecific antibody technology. The proprietary platform generates fully human antibodies which target two specific binding sites with one antibody.

“The kappa-lambda platform is exactly the right technology for therapy areas which need a bispecific antibody that is as close to a natural human antibody as you can get,” said Novimmune CEO Jack Barbut.

Bispecific antibodies currently used in biopharmaceutical applications have been constructed using chemical linkers, non-human material, antibody fragments or forced engineering, he said.

“Our kappa-lambda antibodies are allowed to assemble naturally,” said Head of Research Nicolas Fischer. “So, they have promising development and safety characteristics such as a longer half-life, increased stability and a lower risk of provoking an unwanted reaction in patients.”

Baxalta (NYSE: BXLT) is a newly established global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology.

Novimmune SA is a Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.

Record changed: 2017-07-22


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Novimmune S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top